Mast Therapeutics, Inc. (MSTX) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts MSTX Hot Sheet
Join SI Premium – FREE
Mast Therapeutics, Inc. (NYSE: MSTX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
For earnings history and earnings-related data on Mast Therapeutics, Inc. (MSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norwegian Cruise Line (NCLH) Tops Q3 EPS by 19c; offers guidance
- Bunge Limited (BG) Tops Q3 EPS by 14c
- Merck (MRK) Tops Q3 EPS by 40c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
